-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
KeyCorp Analysts Lower Earnings Estimates for AngioDynamics, Inc. (NASDAQ:ANGO)
KeyCorp Analysts Lower Earnings Estimates for AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) – Research analysts at KeyCorp cut their FY2024 earnings per share estimates for AngioDynamics in a research note issued on Thursday, January 5th. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will post earnings per share of $0.12 for the year, down from their previous estimate of $0.18. The consensus estimate for AngioDynamics' current full-year earnings is $0.01 per share. KeyCorp also issued estimates for AngioDynamics' FY2025 earnings at $0.27 EPS.
Get AngioDynamics alerts:A number of other equities research analysts also recently commented on the company. StockNews.com began coverage on AngioDynamics in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. Raymond James reduced their price target on shares of AngioDynamics from $25.00 to $22.00 and set a "strong-buy" rating for the company in a research report on Friday.
AngioDynamics Price Performance
Shares of ANGO stock opened at $15.17 on Monday. The firm's 50-day moving average is $13.41 and its two-hundred day moving average is $17.87. AngioDynamics has a 12 month low of $11.71 and a 12 month high of $24.87. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.16 and a quick ratio of 1.41. The company has a market capitalization of $593.27 million, a PE ratio of -18.28 and a beta of 0.66.AngioDynamics (NASDAQ:ANGO – Get Rating) last released its earnings results on Thursday, October 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.04). AngioDynamics had a negative net margin of 9.98% and a negative return on equity of 0.14%. The firm had revenue of $81.50 million during the quarter, compared to analysts' expectations of $83.43 million. During the same quarter last year, the business earned ($0.02) EPS. The business's revenue was up 5.8% compared to the same quarter last year.
Hedge Funds Weigh In On AngioDynamics
Several hedge funds and other institutional investors have recently made changes to their positions in ANGO. Texas Permanent School Fund raised its position in shares of AngioDynamics by 2.1% in the 2nd quarter. Texas Permanent School Fund now owns 28,029 shares of the medical instruments supplier's stock valued at $542,000 after purchasing an additional 580 shares in the last quarter. US Bancorp DE boosted its holdings in shares of AngioDynamics by 36.2% in the 2nd quarter. US Bancorp DE now owns 2,562 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 681 shares during the period. Legal & General Group Plc lifted its stake in AngioDynamics by 0.9% in the second quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier's stock valued at $1,802,000 after buying an additional 851 shares during the last quarter. Brinker Capital Investments LLC grew its position in AngioDynamics by 2.3% in the 1st quarter. Brinker Capital Investments LLC now owns 41,539 shares of the medical instruments supplier's stock worth $895,000 after purchasing an additional 929 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its holdings in AngioDynamics by 16.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 6,513 shares of the medical instruments supplier's stock worth $126,000 after buying an additional 934 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company's stock.
About AngioDynamics
(Get Rating)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Recommended Stories
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
AngioDynamic,Inc.(纳斯达克代码:Ango-Get Rating)-KeyCorp的研究分析师在1月5日星期四发布的一份研究报告中下调了对AngioDynamic 2024财年每股收益的预期。KeyCorp分析师M·米山现在预计,这家医疗器械供应商今年的每股收益将为0.12美元,低于此前预期的0.18美元。对AngioDynamic目前全年收益的普遍估计是每股0.01美元。KeyCorp还发布了对AngioDynamic 2025财年每股收益的估计为0.27美元。
到达血管动力学警报:其他一些股票研究分析师最近也对该公司发表了评论。StockNews.com在10月12日星期三的一份研究报告中开始报道AngioDynamic。他们对该股的评级为“持有”。Raymond James将AngioDynamic的股票目标价从25.00美元下调至22.00美元,并在周五的一份研究报告中为该公司设定了“强力买入”评级。
血管动力学性价比
周一,Ango的股票开盘报15.17美元。该公司的50日移动均线切入位在13.41美元,200日移动均线切入位在17.87美元。AngioDynamic的12个月低点为11.71美元,12个月高位为24.87美元。该公司的债务权益比为0.12,流动比率为2.16,速动比率为1.41。该公司市值为5.9327亿美元,市盈率为-18.28,贝塔系数为0.66。AngioDynamic(纳斯达克:Ango-Get Rating)最近一次公布财报是在10月6日(星期四)。这家医疗器械供应商公布了本季度每股收益(0.06美元),低于普遍预期的(0.02美元)和(0.04美元)。AngioDynamic的净利润率为负9.98%,股本回报率为负0.14%。该公司本季度营收为8,150万美元,高于分析师预期的8,343万美元。去年同期,该业务实现每股收益(0.02美元)。与去年同期相比,该业务的收入增长了5.8%。
对冲基金参与AngioDynamic
几家对冲基金和其他机构投资者最近对他们在Ango的头寸进行了调整。德克萨斯永久学校基金在第二季度将其在AngioDynamic股票的头寸提高了2.1%。德克萨斯永久学校基金现在拥有这家医疗器械供应商的28,029股股票,价值542,000美元,上个季度又购买了580股。US Bancorp DE在第二季度增持了36.2%的AngioDynamic股票。在此期间,US Bancorp DE又购买了681股,现在拥有2562股这家医疗器械供应商的股票,价值5万美元。Legal&General Group Plc在第二季度将其在AngioDynamic的持股比例提高了0.9%。Legal&General Group Plc现在拥有这家医疗器械供应商93,102股股票,价值1,802,000美元,上个季度又购买了851股。Brinker Capital Investments LLC在第一季度将其在AngioDynamic的头寸增加了2.3%。Brinker Capital Investments LLC现在拥有这家医疗器械供应商41,539股股票,价值895,000美元,上个季度又购买了929股。最后,美国互惠资本管理有限责任公司在第二季度增持了16.7%的AngioDynamic股份。美国互惠资本管理公司现在持有这家医疗器械供应商6,513股股票,价值12.6万美元,上个季度又购买了934股。机构投资者和对冲基金持有该公司94.94%的股票。
关于血管动力学
(获取评级)
AngioDynamic公司设计、制造和销售各种医疗、手术和诊断设备,由专业保健提供商用于治疗外周血管疾病和血管通路,并用于美国和国际上的肿瘤学和外科环境。
推荐故事
- 免费获取StockNews.com关于血管动力学的研究报告(Ango)
- 理想汽车会成为2023年最不招人恨的中国电动汽车股吗?
- 以下是Snap股票在2023年翻一番的原因
- 哪种流媒体服务股票是2023年最好的?
- MarketBeat:回顾中的一周01/02-01/06
- 为什么CrowdStrike的股价举步维艰?
接受《血管动力学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对AngioDynamic和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧